This study concluded that SGLT-2 inhibitors were associated with decreased risk of cardiovascular outcomes and deaths (Table 8) in patients with T2DM when compared to those treated with other ADAs [1]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.